About this trial
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.
Eligibility criteria
Qualifiers
Patient diagnosed for chronic myelocytic leukemia
Disqualifiers
CML allograft without TKI treatment
Refusal or inability to sign the consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
University Hospital, Clermont-Ferrand
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborator
Bicetre Hospital
Collaborator
University Hospital, Caen
Collaborator
Central Hospital, Nancy, France
Collaborator
University Hospital, Toulouse
Collaborator
CH Annecy Genevois
Collaborator
Rennes University Hospital
Collaborator
Hopital Paul Brousse
Collaborator
Versailles Hospital
Collaborator
Centre Hospitalier Emile Roux
Collaborator
University Hospital, Limoges
Collaborator
Institut Paoli-Calmettes
Collaborator
Centre Hospitalier de Rochefort
Collaborator